abrdn plc Purchases Shares of 708,303 Pyxis Oncology, Inc. (NASDAQ:PYXS)

abrdn plc acquired a new position in Pyxis Oncology, Inc. (NASDAQ:PYXS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 708,303 shares of the company’s stock, valued at approximately $1,275,000.

Several other large investors have also recently modified their holdings of the company. Commonwealth Equity Services LLC acquired a new stake in Pyxis Oncology in the third quarter valued at approximately $26,000. Acadian Asset Management LLC acquired a new stake in shares of Pyxis Oncology in the 3rd quarter worth $26,000. Schulhoff & Co. Inc. purchased a new position in Pyxis Oncology during the 3rd quarter worth $44,000. Radcliffe Capital Management L.P. acquired a new position in Pyxis Oncology during the 3rd quarter valued at about $106,000. Finally, Decheng Capital Management III Cayman LLC purchased a new stake in Pyxis Oncology in the third quarter valued at about $650,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Price Performance

Shares of Pyxis Oncology stock opened at $4.44 on Tuesday. Pyxis Oncology, Inc. has a 1 year low of $1.35 and a 1 year high of $6.85. The stock has a market cap of $258.10 million, a PE ratio of -2.41 and a beta of 1.52. The firm has a fifty day moving average price of $5.08 and a 200 day moving average price of $3.28.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.16. As a group, equities analysts expect that Pyxis Oncology, Inc. will post -0.85 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PYXS. Leerink Partnrs restated an “outperform” rating on shares of Pyxis Oncology in a report on Tuesday, January 23rd. SVB Leerink assumed coverage on Pyxis Oncology in a research report on Tuesday, January 23rd. They issued an “outperform” rating and a $12.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Wednesday, April 10th. BTIG Research assumed coverage on Pyxis Oncology in a research note on Friday, February 9th. They set a “buy” rating and a $8.00 price target on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Friday, March 22nd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $8.50.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.